Dergiler / European Journal of Breast Health / 2019 / Cilt: 15 - Sayı: 2

Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers

Sayfa
125–129
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Besides a statistically significant relationship was found betweenloss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001).Conclusion: In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well astumor aggressiveness.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Breast cancer is the most common cancer among women worldwide.
📊
Temel Bulgular & Veri:Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumorsuppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein.
💡
Sonuç & Katkı:Besides a statistically significant relationship was found betweenloss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001).Conclusion: In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well astumor aggressiveness.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumorsuppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss of ARIDIA proteinexpression in different carcinomas may have a prognostic significance. In the present study, we aimed to evaluate the interactions between ARIDIAloss and molecular subtypes of breast carcinomas.Materials and Methods: ARIDIA expressions were studied in 292 formalin- fixed, paraffin- embedded breast carcinoma specimens and its associationwith different pathological and clinical parameters was evaluated.Results: Loss of ARIDIA expression was detected in 123 cases. There was no statistically significant association between ARID-1A expression andmolecular subtype of breast carcinomas (p=0.110) or HER2 amplification (p=0.909). Contrarily, there was a significant association between ARIDIAexpression and presence of estrogen (p=0.047) or progesterone receptors (p=0.023). Besides a statistically significant relationship was found betweenloss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001).Conclusion: In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well astumor aggressiveness.

🔖

Bu Makaleye Atıf Yap

DİNİZ, G., SAYHAN, S., EKİN, Z. Y., YARDIM, S., SALİMOĞLU, S., ÜNÇEL, M., AKÖZ, G. (2022). Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers. European Journal of Breast Health, Cilt: 15 - Sayı: 2, 125–129. https://ajindex.com/articles/510800

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Akoz G, Diniz G, Ekmekci S, Ekin ZY, Uncel M. Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer. Indian J Pathol Microbiol 2018
  2. [CrossRef] 2. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008
  3. (PMID: 19005198) [CrossRef] 3. Youlken DR, Cramb SM, Dunn NAM, Muller JM, Pyke CM, Baade PD. The Descriptive epidemiology of female breast cancer: An international comprasion of screening, incidence, survival and mortality. Cancer Epidemiology 2012
  4. (PMID: 22459198) [CrossRef] 4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000
  5. (PMID: 10963602) [CrossRef] 5. Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr 2011
  6. (PMID: 22268293) [CrossRef] 6. Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol 2014
  7. (PMID: 25114856) [CrossRef] 7. de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, Straver ME, Vrancken Peeters MJ, Wesseling J, van de Vijver M, Wessels LF, Rodenhuis S. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 2010
  8. (PMID: 19669409) [CrossRef] 8. Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A los correlates with missmatch reparir defiency and intact p53 expression in high grade endometrial carcinomas. Mod Pathol 2014
  9. (PMID: 23887303) [CrossRef] 9. Solakoglu Kahraman D, Diniz G, Sayhan S, Ayaz D, Uncel M, Karadeniz T, Akman T, Ozdemir A. Differences in the ARID-1 alpha expressions in squamous and adenosquamous carcinomas of uterine cervix. APMIS 2015
  10. (PMID: 26303865) [CrossRef] 10. Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D. ARID1A gene mutation in ovarian and endometrial cancers. Oncology Rep 2016
  11. (PMID: 26572704) [CrossRef] 11. Wiegand KC, Sy K, Kallo